Compare Quest Diagnostics Inc (DGX) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs ProShares Ultra QQQ ETF — how do they compare? Quest Diagnostics Inc trades at $230.7 (market cap $25.48B), while ProShares Ultra QQQ ETF trades at $98.37 (market cap $15.38B). The key difference: Quest Diagnostics Inc is the larger of the two by market cap, and Quest Diagnostics Inc pays a 1.49% dividend while ProShares Ultra QQQ ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and ProShares Ultra QQQ ETF for 36 Days on average.
| DGX | QLD | |
|---|---|---|
Market Cap | $25.48B | $15.38B |
Volume | 941,866 | 4,844,085 |
Sector | Health | Leveraged / Inverse |
52-Week High | $247.45 | $100.77 |
52-Week Low | $173.49 | $57.16 |
Typical Hold Time | 56 Days | 36 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
QLD (ProShares Ultra QQQ ETF) trades at $98.12, down 2.11% on the day. Technical indicators show a bullish trend with moving averages supporting upside momentum while oscillators remain neutral. The ETF benefits from 2x leverage on the Nasdaq-100, providing amplified exposure to large-cap tech stocks. Recent institutional buying and media coverage highlight continued investor interest in leveraged tech exposure.
Outlook remains cautiously optimistic given the bullish technical setup and institutional accumulation, though leveraged ETFs carry elevated volatility risks during market downturns. The key opportunity lies in continued tech sector strength, while the primary risk involves amplified losses if the Nasdaq-100 declines significantly.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
